rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
Most BRAF (V600E) mutant melanomas are sensitive to selective BRAF inhibitors, but BRAF mutant colon cancers are intrinsically resistant to these drugs because of feedback activation of EGFR.
|
26365186 |
2015 |
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
KRAS and BRAF (V600E) mutations are important predictive and prognostic markers, respectively, in colon cancer, but little is known about patient and clinical factors associated with them.
|
24925349 |
2014 |
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
MSI and the BRAF(V600E) mutation have a prognostic impact in colon cancer.
|
24964758 |
2014 |
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
The prevalence of BRAF(V600E) was considerably higher in older (age > 70) females with KRAS wild-type right-sided colon cancers (50%) compared to the unselected cohort (10%).
|
20635392 |
2011 |
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
Colon cancers carrying BRAF V600E and β-catenin T41A activating mutations are resistant to numerous common anticancer drugs.
|
29541216 |
2018 |
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.
|
29127628 |
2019 |
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E was associated with advanced TNM (P < 0.001), more distant metastases (P = 0.025), and worse overall survival (OS, P < 0.001; multivariate HR = 4.2, P = 0.004) in colon cancer patients.
|
25367198 |
2014 |
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
The clinical studies in the manuscript by Al-Marrawi et al. describe the rational combination of signaling inhibitors in a colon cancer patient whose tumor cells express a mutant active B-RAF V600E protein that signals into the MEK1/2-ERK1/2 pathway downstream of K-RAS; this is a particularly aggressive form of colon cancer for which few rational therapeutic interventions have been available until recent times.
|
24025253 |
2013 |
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8-10% of all colon cancers), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.
|
22281684 |
2012 |
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
In 212 RAS wild-type patients, V600E mutation was higher in older patients (9.5% vs. 2.2%, p=0.017), women (9.2% vs. 2.2%, p=0.021) and right-sided CRCs (10.5% vs. 3.4%, p=0.06). dMMR was detected in 7.75% of all stages of CRCs, with the highest dMMR rate of 40% in stage II right-sided colon cancer.
|
28416767 |
2017 |